DIA 2023: Cal Collins Discusses SMART on FHIR and Supply Chains

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

The CRO earned a Bronze rating for criteria based on environmental, social, and ethical performance.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

The CDMO’s boost in production will be centered around pharmaceutical products.

There is no doubt that drug shortages are a detriment to the pharma supply chain, but how commonplace were they during the COVID era?